The U.S. Justice Department announced charges against 601 people including doctors and nurses for taking part in healthcare fraud and opioid-related crimes that resulted in more than $2 billion in losses.

Theranos Inc. founder Elizabeth Holmes and the embattled blood-testing company’s former president were indicted on charges that they engaged in schemes to defraud investors, doctors and patients, the U.S. Justice Department announced.

The U.S. Justice Department said the part of Obamacare requiring individuals to have health insurance is unconstitutional, an unusual move that could lead to stripping away some of the most significant and popular parts of the law.

Minnesota became the latest state to sue Insys Therapeutics Inc., accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

Jazz Pharmaceuticals Plc agreed to pay $57 million to resolve a U.S. probe into the company’s financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

The U.S. Justice Department sought court permission to participate in settlement negotiations aimed at resolving lawsuits by state and local governments against opioid manufacturers and distributors.

The U.S. Justice Department asked a federal judge overseeing hundreds of lawsuits against opioid manufacturers and distributors to give it 30 days to decide whether to participate in the litigation.

U.S. President Donald Trump called for a federal lawsuit against opioid companies and stiffer penalties for drug dealers, arguing that the government must take a strong approach to combat an opioid addiction epidemic.

OxyContin maker Purdue Pharma LP has cut its sales force in half and will stop promoting opioids to physicians, following widespread criticism of the ways that drugmakers market addictive painkillers.

Maryland’s attorney general filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc. as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.